Boehringer and ZEISS partnership eye diseases
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
Search
Lameness horses collaboration Sleip app artificial intelligence
The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone.
global-top-employer
For the first time, Boehringer Ingelheim receives the award as a Global Top Employer as well as individual awards in 27 countries.
Boehringer Ingelheim Ruminant Well-Being Awards 2020
The World Association for Buiatrics and Boehringer Ingelheim announce the Ruminant Well-Being Awards.
Reduction of Salmonella in swine after vaccination
Authorities acknowledge reduction of Salmonella after vaccination with Enterisol® Ileitis
Winners of the 2020 European PRRS Research Award
Winners of the 2020 European PRRS Research Award announced Three winner awarded 25,000 euro each for their research.
Agreement-to-acquire-Labor-Dr.-Merk
Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
EMA authorization for Reprocyc ParvoFLEX
Boehringer Ingelheim obtains EMA authorization for Reprocyc® ParvoFLEX, a new porcine parvovirus vaccine
Winners of the 2019 European PRRS Research Award
Winners of the 2019 European PRRS Research Award announced.
FRONTLINE becomes Brand of the Year 2019-2020
FRONTLINE becomes ‘Brand of the Year’ 2019-2020 in World Branding Awards
Boehringer Ingelheim opens Health Management Centre in China
Boehringer Ingelheim opens Health Management Centre in China The new Health Management Centre integrates animal disease and health diagnostics as well as monitoring tools The centre further strengthens the company’s ability to provide services along the f
Launch of Frontline flagship store on Tmall
Boehringer Ingelheim launches Frontline flagship store on Tmall to sell selling full range of pet parasiticides.
FDA accepts new chronic kidney disease treatment application
FDA accepts new chronic kidney disease treatment application
Boehringer Ingelheim invests in precision cancer treatments
Boehringer Ingelheim Venture Fund invests in Synthetica as part of its commitment to advancing innovative, next-generation cancer therapies
FDA Grants Breakthrough Status to Schizophrenia Treatment
Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough Device Designation for schizophrenia prescription digital therapeutic
Groundbeaking of vaccine production center in France
Boehringer Ingelheim breaks ground on its strategic vaccine production center for veterinary public health
Winners of BVDzero Scholarship Programme
Boehringer Ingelheim announces winners of BVDzero Scholarship Programme
Boehringer Ingelheim and Fraunhofer partnership
Boehringer Ingelheim and Fraunhofer IME launch collaboration which aims to develop sustainable animal health products
Henke-Sass Wolf develop needle free device
Boehringer Ingelheim partners with Henke-Sass, Wolf to develop innovative needle free injection device for pigs
New vaccine against Bovine Respiratory Disease
Boehringer Ingelheim’s Bovalto Respi Intranasal is a new respiratory vaccine for active immunization of cattle against Bovine Respiratory Disease.
New production center for Veterinary Public Health
Boehringer Ingelheim invests more than €200 million to establish a strategic production center for Veterinary Public Health in Lyon, France.
Official partner to Cat Care for Life
Boehringer Ingelheim announces its new partnership with the CatCareforLife program.
Survey with Ipsos to gain insights human-animal bond
Boehringer Ingelheim partnered with the Ipsos Research Institute to carry out a survey to explore the human-animal bond.
Winners of 2020 BVDzero Case Awards
Winners of 2020 BVDzero Case Awards announced. 10 top clinical cases will receive a total prize of 15,000 euros.
Approval for Aservo EquiHaler equine asthma therapy
Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy